| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers B > Headlines for Boston Scientific Corp. > News item |
Boston Scientific: Pulse generator for migraine treatment implanted in first patient
By Lisa Kerner
Erie, Pa., April 17 - Boston Scientific Corp. said the first patient in the Prism (Precision Implantable Stimulator for Migraine) clinical trial was implanted with the Precision neurostimulation system. The implantable pulse generator will deliver electrical impulses to the occipital nerves located just under the skin at the back of the neck.
The patient, a 52 year-old woman, currently experiences more than 20 headache days per month and has suffered from headaches for the last 32 years, according to a company news release.
This pivotal trial will assess the safety and efficacy of occipital nerve stimulation as a treatment for refractory migraine headache using Boston Scientific's neurostimulation system to treat migraine patients who do not respond to other available therapies or who cannot tolerate the side effects of existing medications.
"This randomized, placebo-controlled trial is an important step to providing scientific validation for the use of neurostimulation as a treatment for migraines," Roger Cady, an investigator in the study, said in the release.
"More than 4,000 pain sufferers are benefiting from the Precision system, and we are committed to making this same technology available to provide headache relief to migraine patients," the president of Boston Scientific's Neuromodulation Group, Jeff Greiner, added in the release.
An estimated 28 million suffer from migraine in the United States, costing employers $13 billion annually in lost work and productivity.
Based in Natick, Mass., Boston Scientific develops, manufactures and markets medical devices.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.